The Latest Breaking News on Pharma

Sterigenics, its parent company and a corporate predecessor should pay $363 million in damages for exposing a Willowbrook, Illinois, woman and thousands of others to cancer-causing ethylene oxide pollution, a Cook County jury decided Monday.

Humans were losing the war against antibiotic-resistant superbugs. Is that about to change?

Someone with a lot of money to spend has taken a bullish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

According to WHO data, the rates of typical childhood vaccinations have only fallen a point between 2021 and 2020

Dr. Nelson Onaro conceded last summer that he’d written illegal prescriptions, although he said he was thinking only of his patients. From a tiny clinic in Oklahoma, he doled out hundreds of opioid pills and dozens of fentanyl patches with no legitimate medical purpose.

Recently listed biotech stock Comera Life Sciences is trading near its 52-week low. The stock is down more than 75% year-to-date. Although the $15 million purchase agreement with Arena Business Solutions is expected to help it invest in its product pipeline and formulation platform SQore, will it be wise to…

Brazilian national health regulator Anvisa has approved the COVID-19 vaccine produced by Pfizer and BioNTech for children aged between six months and four years, the government body said in a statement Friday night.

Biotechnology company, bluebird bio, Inc. (NASDAQ: BLUE) announced late Friday that the Food and Drug Administration approved its gene therapy for a rare neurodegenerative disease.

Amid the highly uncertain market conditions, investors must look for stocks with ample room for growth and better stability. Biopharmaceutical major Pfizer’s (PFE) products remain in demand irrespective of economic cycles. Given its robust financials, discounted valuation, and high profitability, it could be wise to invest in this defensive stock.…

Biopharmaceutical giant Gilead Sciences (GILD) has delivered solid segmental sales growth in the last reported quarter. In addition, the company’s various research breakthroughs and drug approvals should further bolster its performance in the coming months. Given its robust profitability and discounted valuation, we think it could be wise to scoop…

Biotech company bluebird bio (BLUE) received FDA approval for ZYNTEGLO last month, which seems to have boosted its stock price. However, given its bleak profitability and stretched valuations, the stock might be best avoided. Read on….